Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Australian university scientists design new diflunisal esters with improved characteristics

Dec. 8, 1998

Centocor will market Retavase exclusively in the U.S. starting in January

Dec. 4, 1998

Pharming and Gem to codevelop human lactoferrin (GPX-400) to neutralize heparin

Dec. 4, 1998

rNAPc2 enters phase II trials in U.S. and Europe

Dec. 3, 1998

First clinical trial of human gene therapy for hemophilia begins

Dec. 3, 1998

U.S. patent covers transgenically produced rhATIII

Dec. 3, 1998

Microbix and Gensia Sicor terminate licensing agreement

Dec. 2, 1998

Preclinical studies of XV-454 support further testing of novel fibrinogen antagonist

Dec. 1, 1998

Searle revises OPUS-TIMI 16 trial evaluating orbofiban acetate

Nov. 25, 1998

Two new antiplatelet agents marketed in Germany

Nov. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.